×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Postpartum Depression Market

ID: MRFR/HC/25983-HCR
100 Pages
Rahul Gotadki
October 2025

Postpartum Depression Market Research Report: Size, Share, Trend Analysis By Treatment (Medication, Psychotherapy, Lifestyle Changes, Electroconvulsive Therapy, Transcranial Magnetic Stimulation), By Severity (Mild, Moderate, Severe, Postpartum Psychosis), By Age Group (15-24 years, 25-34 years, 35-44 years, 45 years and above), By Onset (Within 4 weeks postpartum, Between 4 weeks and 12 months postpartum, More than 12 months postpartum), By Risk Factors (History of depression or anxiety, Hormonal changes, Sleep deprivation, Stressful life e... read more

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Postpartum Depression Market Infographic
×
Postpartum Depression Market Infographic Full View
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Postpartum Depression Market Summary

As per MRFR analysis, the Postpartum Depression Market Size was estimated at 15.38 USD Billion in 2024. The Postpartum Depression industry is projected to grow from 16.16 USD Billion in 2025 to 26.61 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.11 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Postpartum Depression Market is experiencing significant growth driven by increased awareness and advancements in treatment.

  • North America remains the largest market for postpartum depression treatments, reflecting a robust healthcare infrastructure.
  • The Asia-Pacific region is emerging as the fastest-growing market, driven by rising awareness and access to mental health services.
  • Medication continues to dominate the market, while psychotherapy is rapidly gaining traction as the fastest-growing segment.
  • The rising incidence of postpartum depression and an increased focus on maternal mental health are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 15.38 (USD Billion)
2035 Market Size 26.61 (USD Billion)
CAGR (2025 - 2035) 5.11%

Major Players

AbbVie Inc (US), Pfizer Inc (US), H. Lundbeck A/S (DK), AstraZeneca PLC (GB), Eli Lilly and Company (US), Johnson & Johnson (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Otsuka Pharmaceutical Co., Ltd. (JP)

Postpartum Depression Market Trends

The Postpartum Depression Market is currently experiencing a notable evolution, driven by an increasing awareness of maternal mental health. This heightened consciousness among healthcare providers and the general public appears to be fostering a more supportive environment for women experiencing postpartum challenges. As a result, there is a growing demand for effective treatment options, including therapy and medication, which may lead to enhanced accessibility and affordability of mental health services. Furthermore, the integration of technology in healthcare, such as teletherapy and mobile applications, seems to be transforming the landscape of postpartum care, providing mothers with convenient resources to manage their mental well-being. In addition, the Postpartum Depression Market is likely to benefit from ongoing research and development efforts aimed at understanding the complexities of maternal mental health. This research may uncover new therapeutic approaches and interventions, potentially improving outcomes for affected individuals. Moreover, collaborations between healthcare organizations and advocacy groups could further amplify the focus on postpartum depression, ensuring that it remains a priority within maternal health initiatives. Overall, the market appears poised for growth, with a multifaceted approach to addressing the needs of mothers experiencing postpartum depression.

Increased Awareness and Education

There is a growing emphasis on educating both healthcare professionals and the public about postpartum depression. This trend indicates a shift towards recognizing the importance of mental health in the postpartum period, which may lead to earlier diagnosis and intervention.

Technological Integration in Treatment

The incorporation of technology into treatment modalities is becoming more prevalent. Telehealth services and mental health applications are emerging as viable options for mothers, potentially increasing access to care and providing support in a more flexible manner.

Research Advancements in Maternal Mental Health

Ongoing research into postpartum depression is likely to yield new insights and treatment options. This trend suggests a commitment to understanding the underlying causes and developing innovative therapies that could enhance the quality of care for affected mothers.

Postpartum Depression Market Drivers

Rising Awareness of Mental Health

The increasing awareness surrounding mental health issues, particularly postpartum depression, plays a crucial role in the Global Postpartum Depression Market Industry. As societal stigma diminishes, more women are encouraged to seek help and treatment. Educational campaigns and healthcare initiatives are actively promoting understanding of postpartum depression, leading to higher diagnosis rates. This heightened awareness is projected to contribute to the market's growth, with estimates suggesting a market value of 15.4 USD Billion in 2024. The focus on mental health is likely to continue influencing healthcare policies, thereby enhancing support systems for new mothers globally.

Market Segment Insights

By Treatment Type: Medication (Largest) vs. Psychotherapy (Fastest-Growing)

In the Postpartum Depression Market, Medication continues to hold the largest market share among treatment types, predominantly comprising antidepressants and mood stabilizers. It is favored for its efficacy and rapid onset of action, making it a go-to option for many healthcare providers. Psychotherapy, while currently smaller in overall share, has been gaining traction as a highly effective treatment modality, particularly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT), appealing to parents looking for non-pharmacological approaches.

Medication (Dominant) vs. Psychotherapy (Emerging)

Medication remains the dominant treatment for postpartum depression, characterized by a wide variety of pharmaceutical options that meet diverse patient needs. This segment benefits from ongoing research and development, leading to new formulations and improved delivery methods. On the other hand, Psychotherapy is emerging rapidly in this market as an appealing alternative or complement to medication. With increasing recognition of mental health, more women are seeking counseling services, which emphasize personalized care and coping strategies. This growing acceptance and integration of psychological support into treatment plans signify a shift towards holistic management of postpartum depression.

By Severity Level: Moderate (Largest) vs. Severe (Fastest-Growing)

In the Postpartum Depression Market, the distribution of severity levels reveals that moderate cases hold the largest share, reflecting a significant portion of affected individuals seeking treatment. On the other hand, severe postpartum depression is gaining attention and recognition, showing promising growth potential as awareness increases and more effective treatment options become available. Understanding this distribution is essential for tailoring intervention strategies and resource allocation in the field.

Moderate (Dominant) vs. Severe (Emerging)

Moderate postpartum depression is characterized by notable symptoms that impair daily functioning but do not completely disrupt it, making it a dominant force in the market. This segment is recognized for its high prevalence, as many women experience moderate symptoms during the postpartum period. Emerging in focus, severe postpartum depression presents with more intense symptoms that often require urgent care and intervention. The increasing visibility of this severe category is being driven by heightened awareness of maternal mental health, leading to a demand for improved screening and treatment protocols.

By Demographic Factors: Age (Largest) vs. Income Level (Fastest-Growing)

In the postpartum depression market, age demographics reveal that younger mothers, particularly those between 18 to 34 years, represent the largest segment. This group commonly experiences significant shifts in mental health due to the challenges of new motherhood. In contrast, the 35 and older demographic, while smaller, also sees notable incidences of postpartum depression, albeit more commonly due to the complexities of parenting at an older age. Furthermore, income levels show an interesting trend; women from lower-income backgrounds are reportedly engaging more with mental health services, highlighting a growing vigilance in addressing postpartum challenges. The growth of income level as a contributing factor to postpartum depression is underscored by the increasing accessibility of mental health resources and awareness initiatives targeted at lower-income populations. The rise in awareness and discourse around mental health has encouraged women from diverse income brackets to seek help more frequently, contributing to rapid growth in this segment. Factors like community support programs and increased funding for maternal mental health services are eliminating barriers, facilitating a wave of support among postpartum women in various income categories.

Age: 18-34 (Dominant) vs. Income Level: Low-Income (Emerging)

In the postpartum depression market, the age group of 18 to 34 stands out as a dominant segment. Women in this category face unique pressures and lifestyle changes that often contribute to mental health struggles following childbirth. Factors such as limited social support and the transition into motherhood at a young age intensify the challenges they encounter. Their ample engagement with digital platforms also facilitates the spread of information regarding postpartum depression, helping to normalize their experiences and drive the demand for solutions. Emergent within this landscape is the low-income segment, which is increasingly recognized as a crucial demographic. Low-income mothers often face additional stressors, including financial insecurity, which can exacerbate postpartum depression symptoms. As mental health awareness improves, we see a corresponding rise in service engagement among these women, leading to enhanced visibility and advocacy for tailored support.

By Duration of Symptoms: 3 to 6 Months (Largest) vs. More than 12 Months (Fastest-Growing)

The 'Duration of Symptoms' segment within the Postpartum Depression Market reveals a diverse landscape of symptom persistence among new mothers. The category of '3 to 6 Months' accounts for the largest share, indicating a significant portion of women experiencing extended depressive symptoms within this timeframe. Conversely, the 'More than 12 Months' segment is identified as the fastest-growing, reflecting increasing awareness and diagnosis of long-term postpartum depression symptoms that demand attention and care.

3 to 6 Months (Dominant) vs. More than 12 Months (Emerging)

The '3 to 6 Months' segment remains dominant in the Postpartum Depression Market, characterized by a notable prevalence of new mothers who face significant emotional challenges during this critical period. This duration represents a window where support options and treatment interventions are crucial, as many women report challenges in managing their mental health. Meanwhile, the 'More than 12 Months' segment is emerging rapidly, indicating a shift towards recognizing the chronic nature of postpartum depression. This growth is driven by heightened awareness among healthcare providers and families regarding the long-term impact of untreated postpartum issues, leading to an increased demand for tailored treatment approaches.

By Awareness and Education: High Awareness (Largest) vs. Low Awareness (Emerging)

In the Postpartum Depression Market, the distribution of segment values by awareness levels reveals a striking contrast. High Awareness currently holds the largest share, driven by increased public discussions and advocacy surrounding maternal mental health. Meanwhile, Moderate Awareness acts as a bridging segment, indicating a pronounced gap in understanding that could be influenced by tailored educational initiatives. Low Awareness, though emerging, still reflects a significant portion of those unaware of postpartum depression and its impacts, highlighting critical areas for growth and intervention. Current trends illustrate a growing recognition of postpartum depression, thanks to campaigns promoting mental health during and after pregnancy. High Awareness segments are encouraged by increasing dialogues among healthcare professionals and the community, advocating for holistic support systems. The rise of social media and online resources further propels awareness initiatives, although the Moderate and Low Awareness segments signify substantial opportunities for growth, particularly through targeted educational programs and outreach strategies to elevate understanding and address the stigma linked to postpartum mental health issues.

High Awareness (Dominant) vs. Low Awareness (Emerging)

The High Awareness segment in the Postpartum Depression Market is characterized by widespread understanding, driven by media exposure and educational campaigns. This dominant segment encompasses individuals who not only recognize postpartum depression but also seek effective treatments and support systems. Conversely, the Low Awareness segment remains an emerging space, primarily consisting of new mothers who may not fully grasp postpartum depression's prevalence or the symptoms to look for. This disparity underscores a significant market opportunity where enhanced educational efforts can foster awareness and improve overall mental health. The potential for growth lies in bridging the knowledge gap through targeted outreach, support groups, and accessible resources to empower women and families.

Get more detailed insights about Postpartum Depression Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America is poised to maintain its leadership in the postpartum depression market, holding a significant market size of $7.69 billion in 2025. Key growth drivers include increasing awareness of mental health issues, supportive healthcare policies, and advancements in treatment options. The region's regulatory environment is favorable, promoting research and development in postpartum care, which is crucial for addressing the rising demand for effective therapies. The United States and Canada are the leading countries in this market, with major pharmaceutical companies like AbbVie Inc, Pfizer Inc, and Johnson & Johnson actively involved. The competitive landscape is characterized by a mix of established players and emerging biotech firms, all striving to innovate and expand their product offerings. This dynamic environment is expected to foster collaboration and investment, further enhancing market growth.

Europe : Growing Awareness and Support

Europe is witnessing a growing focus on postpartum depression, with a market size of $4.62 billion projected for 2025. Factors driving this growth include increased awareness of maternal mental health, supportive government initiatives, and a rise in healthcare spending. Regulatory bodies are actively promoting mental health programs, which are essential for improving access to treatment and support for affected women across the region. Leading countries such as Germany, France, and the UK are at the forefront of this market, with key players like H. Lundbeck A/S and AstraZeneca PLC making significant contributions. The competitive landscape is evolving, with a mix of established pharmaceutical companies and innovative startups. This diversity is crucial for developing new therapies and improving existing treatment options, ensuring that the needs of postpartum women are met effectively.

Asia-Pacific : Emerging Powerhouse in Healthcare

The Asia-Pacific region is emerging as a significant player in the postpartum depression market, with a projected market size of $2.77 billion by 2025. Key growth drivers include increasing awareness of mental health issues, rising disposable incomes, and expanding healthcare infrastructure. Governments are beginning to recognize the importance of maternal mental health, leading to more supportive policies and initiatives aimed at improving access to care. Countries like Japan, Australia, and China are leading the charge in this market, with a growing presence of key players such as Otsuka Pharmaceutical Co., Ltd. and Eli Lilly and Company. The competitive landscape is characterized by a mix of local and international firms, all vying to capture market share. This dynamic environment is fostering innovation and collaboration, which are essential for addressing the unique challenges faced by postpartum women in the region.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa region represents an untapped market for postpartum depression solutions, with a market size of $0.3 billion projected for 2025. Key challenges include limited awareness of mental health issues, inadequate healthcare infrastructure, and cultural stigmas surrounding mental health. However, there is a growing recognition of the need for mental health support, which is beginning to drive demand for effective treatments and interventions. Countries such as South Africa and the UAE are starting to prioritize maternal mental health, with some initiatives aimed at improving access to care. The competitive landscape is still developing, with few key players currently active in the market. However, as awareness increases and healthcare systems improve, there is significant potential for growth in this region, attracting both local and international investments.

Key Players and Competitive Insights

The Postpartum Depression Market is currently characterized by a dynamic competitive landscape, driven by increasing awareness of maternal mental health and the growing demand for effective treatment options. Key players such as AbbVie Inc (US), Pfizer Inc (US), and H. Lundbeck A/S (DK) are strategically positioning themselves through innovation and partnerships. AbbVie Inc (US) has focused on expanding its product portfolio, while Pfizer Inc (US) emphasizes research and development to enhance treatment efficacy. H. Lundbeck A/S (DK) is leveraging collaborations with healthcare providers to improve patient access to therapies, collectively shaping a competitive environment that prioritizes patient-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several players vying for market share. The collective influence of these key players is significant, as they drive advancements in treatment methodologies and foster a competitive atmosphere that encourages innovation and collaboration. In November 2025, AbbVie Inc (US) announced a strategic partnership with a leading telehealth provider to enhance access to postpartum depression treatments. This collaboration is expected to facilitate remote consultations and improve patient engagement, thereby expanding AbbVie’s reach in the market. The strategic importance of this move lies in its potential to address barriers to care, particularly in underserved regions, aligning with the growing trend of digital health solutions. In October 2025, Pfizer Inc (US) launched a new digital platform aimed at providing resources and support for new mothers experiencing postpartum depression. This initiative not only reflects Pfizer's commitment to maternal health but also positions the company as a leader in integrating technology into mental health care. The platform is likely to enhance patient education and support, fostering a more informed patient base that can actively participate in their treatment journey. In September 2025, H. Lundbeck A/S (DK) expanded its clinical trial program for a novel antidepressant specifically targeting postpartum depression. This strategic move underscores the company's dedication to advancing treatment options and addressing unmet needs in the market. By investing in research and development, H. Lundbeck aims to solidify its position as a key player in the postpartum depression space, potentially leading to breakthroughs that could redefine treatment paradigms. As of December 2025, current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the landscape, as companies recognize the value of collaboration in enhancing service delivery and patient outcomes. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technology integration, and supply chain reliability, reflecting a broader shift towards holistic and patient-centered care.

Key Companies in the Postpartum Depression Market include

Industry Developments

  • Q3 2023: FDA approves first oral treatment for postpartum depression The U.S. Food and Drug Administration approved Zurzuvae (zuranolone), developed by Sage Therapeutics and Biogen, as the first oral medication for postpartum depression, marking a significant milestone in treatment options for the condition.
  • Q3 2023: Sage Therapeutics and Biogen Announce FDA Approval of ZURZUVAE™ (zuranolone) for Adults with Postpartum Depression Market (PPD) Sage Therapeutics and Biogen received FDA approval for ZURZUVAE, the first and only oral, once-daily, 14-day treatment specifically indicated for adults with postpartum depression.
  • Q1 2024: Biogen and Sage Therapeutics Announce U.S. Commercial Launch of ZURZUVAE™ (zuranolone) for Postpartum Depression Market Biogen and Sage Therapeutics announced the U.S. commercial launch of ZURZUVAE, making the first oral treatment for postpartum depression available to patients nationwide.
  • Q2 2024: GH Research Initiates Phase 2 Clinical Trial of GH001 in Postpartum Depression Market GH Research announced the initiation of a Phase 2 clinical trial evaluating GH001, an investigational therapy, in women with postpartum depression.
  • Q1 2025: Reunion Neuroscience Receives FDA Fast Track Designation for RE104 in Postpartum Depression Market Reunion Neuroscience announced that the FDA granted Fast Track designation to its investigational drug RE104 for the treatment of postpartum depression, aiming to expedite its development and review.
  • Q1 2025: Lipocine Announces Positive Topline Results from Phase 2 Study of LPCN 1154 in Women with Postpartum Depression Market Lipocine reported positive topline results from its Phase 2 clinical trial of LPCN 1154, a novel oral therapy candidate for postpartum depression.
  • Q1 2025: Brii Biosciences Announces IND Clearance by FDA for BRII-296 in Postpartum Depression Market Brii Biosciences announced that the U.S. FDA cleared its Investigational New Drug (IND) application for BRII-296, allowing the company to begin clinical trials in postpartum depression.

Future Outlook

Postpartum Depression Market Future Outlook

The Postpartum Depression Market is projected to grow at a 5.11% CAGR from 2024 to 2035, driven by increased awareness, improved treatment options, and supportive healthcare policies.

New opportunities lie in:

  • Development of telehealth platforms for postpartum support services.
  • Creation of targeted pharmaceutical solutions for diverse demographics.
  • Expansion of community-based mental health programs focusing on postpartum care.

By 2035, the market is expected to be robust, reflecting enhanced treatment accessibility and awareness.

Market Segmentation

Postpartum Depression Market Severity Level Outlook

  • Mild
  • Moderate
  • Severe
  • Chronic

Postpartum Depression Market Treatment Type Outlook

  • Psychotherapy
  • Medication
  • Support Groups
  • Lifestyle Changes

Postpartum Depression Market Demographic Factors Outlook

  • Age
  • Income Level
  • Education Level
  • Marital Status

Postpartum Depression Market Duration of Symptoms Outlook

  • Less than 3 Months
  • 3 to 6 Months
  • 6 to 12 Months
  • More than 12 Months

Postpartum Depression Market Awareness and Education Outlook

  • High Awareness
  • Moderate Awareness
  • Low Awareness

Report Scope

MARKET SIZE 2024 15.38(USD Billion)
MARKET SIZE 2025 16.16(USD Billion)
MARKET SIZE 2035 26.61(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.11% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled AbbVie Inc (US), Pfizer Inc (US), H. Lundbeck A/S (DK), AstraZeneca PLC (GB), Eli Lilly and Company (US), Johnson & Johnson (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Otsuka Pharmaceutical Co., Ltd. (JP)
Segments Covered Treatment Type, Severity Level, Demographic Factors, Duration of Symptoms, Awareness and Education
Key Market Opportunities Integration of digital therapeutics and telehealth solutions in the Postpartum Depression Market.
Key Market Dynamics Rising awareness and treatment options for postpartum depression drive market growth and innovation in therapeutic solutions.
Countries Covered North America, Europe, APAC, South America, MEA
Leave a Comment

FAQs

What is the projected growth of the Postpartum Depression market?

The Postpartum Depression market is the expected increase in total market value of 26.61 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.

What is the size of the Postpartum Depression market?

Postpartum Depression market size was valued at approximately 15.38 billion USD in 2024. This figure will reach 26.61 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.

What is the CAGR of the Postpartum Depression market?

Postpartum Depression market is expected to grow at a CAGR of 5.11% between 2025 and 2035.

How much will the Postpartum Depression market be worth by 2035?

Postpartum Depression market is expected to be worth of 26.61 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.

How will the Postpartum Depression market perform over the next 10 years?

Over the next 10 years the Postpartum Depression market is expected to shift from usd billion 15.38 to 26.61 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.

What is the largest regional segment of the Postpartum Depression Market?

North America is the largest regional segment of the Postpartum Depression Market, accounting for a significant share of the global market.

What are the key growth drivers of the Postpartum Depression Market?

Rising awareness about postpartum depression, increasing prevalence of postpartum depression, and growing demand for effective treatments are key growth drivers of the Postpartum Depression Market.

Who are the major competitors in the Postpartum Depression Market?

Major competitors in the Postpartum Depression Market include pharmaceutical companies, medical device manufacturers, and healthcare providers.

What are the major applications of postpartum depression treatments?

Major applications of postpartum depression treatments include diagnosis, prevention, and treatment of postpartum depression.

What are the challenges faced by the Postpartum Depression Market?

Challenges faced by the Postpartum Depression Market include stigma associated with mental health issues, lack of awareness, and limited access to healthcare services.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓